Table 1. Baseline characteristics of the patients according to the NLR, dNLR, PLR and LMR.
| Variables | Total | NLR | P value | dNLR | P value | PLR | P value | LMR | P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤1.34 | >1.34 | ≤1.34 | >1.34 | ≤185.5 | >185.5 | ≤3.11 | >3.11 | ||||||
| No. of patients | No. of patients | No. of patients | No. of patients | ||||||||||
| 229 (34.6%) | 432 (65.4%) | 354 (53.6%) | 307 (46.4%) | 579 (87.6%) | 82 (12.4%) | 41 (6.2%) | 620 (93.8%) | ||||||
| Age | |||||||||||||
| ≤50 years | 348 (52.6%) | 108 (31.0%) | 240 (69.0%) | 0.040 | 172 (49.4%) | 176 (50.6%) | 0.025 | 301 (86.5%) | 47 (13.5%) | 0.366 | 22 (6.3%) | 326 (93.7%) | 0.894 |
| >50 years | 313 (47.4%) | 121 (38.7%) | 192 (61.3%) | 182 (41.9%) | 131 (41.95%) | 278 (88.8%) | 35 (11.2%) | 19 (6.1%) | 294 (93.9%) | ||||
| Lymphocyte count (109 cells/L)a | 2.148 (0.821) | 2.535 (0.967) | 1.942 (0.645) | <0.001 | 2.402 (0.911) | 1.855 (0.581) | <0.001 | 2.269 (0.791) | 1.293 (0.434) | <0.001 | 1.372 (0.548) | 2.201 (0.810) | <0.001 |
| Neutrophil count (109 cells/L)a | 3.639 (1.691) | 2.569 (1.076) | 4.206 (1.684) | <0.001 | 2.823 (1.132) | 4.578 (1.741) | <0.001 | 3.578 (1.548) | 4.073 (2.448) | 0.013 | 4.776 (3.115) | 3.564 (1.527) | <0.001 |
| Platelet count (109 cells/L)a | 259.053 (61.584) | 248.812 (60.511) | 264.481 (61.526) | 0.002 | 251.201 (58.529) | 268.107 (63.834) | <0.001 | 252.242 (55.558) | 307.246 (78.762) | <0.001 | 249.610 (87.644) | 259.677 (59.508) | 0.311 |
| Monocyte count (109 cells/L)a | 0.381 (0.175) | 0.350 (0.176) | 0.398 (0.173) | 0.001 | 0.370 (0.183) | 0.394 (0.165) | 0.086 | 0.386 (0.174) | 0.348 (0.177) | 0.068 | 0.618 (0.240) | 0.365 (0.158) | <0.001 |
| Sex | |||||||||||||
| Female | 658 (99.5%) | 228 (34.7%) | 430 (65.3%) | 0.999b | 353 (53.6%) | 305 (46.4%) | 0.600b | 576 (87.5%) | 82 (12.5%) | 0.999b | 41 (6.2%) | 616 (93.8%) | 0.999b |
| Male | 3 (0.5%) |
1 (33.3%) | 2 (66.7%) | 1 (33.3%) |
2 (66.7%) |
3 (100%) |
0 | 0 | 3 (100%) |
||||
| Operation | |||||||||||||
| Lumpectomy | 362 (54.8%) | 126 (34.8%) | 236 (65.2%) | 0.923 | 194 (53.6%) | 168 (46.4%) | 0.984 | 324 (89.5%) | 38 (10.5%) | 0.102 | 15 (4.1%) | 347 (95.9%) | 0.015 |
| Mastectomyc | 299 (45.2%) | 103 (34.4%) | 196 (65.6%) | 160 (53.5%) | 139 (46.5%) | 255 (85.3%) | 44 (14.7%) | 26 (8.7%) | 272 (91.3%) | ||||
| Multiplicity | |||||||||||||
| Solitary tumor | 593 (89.7%) | 207 (34.9%) | 386 (65.1%) | 0.675 | 318 (53.6%) | 275 (46.4%) | 0.915 | 518 (87.4%) | 75 (12.6%) | 0.577 | 36 (6.1%) | 556 (93.9%) | 0.600b |
| Multiple tumors | 68 (10.3%) | 22 (32.4%) | 46 (67.6%) | 36 (52.9%) | 32 (47.1%) | 61 (89.7%) |
7 (10.3%) | 5 (7.4%) |
63 (92.6%) | ||||
| Histologic grade | |||||||||||||
| 1 | 183 (27.7%) | 62 (33.9%) | 121 (66.1%) | 0.965 | 98 (53.6%) | 85 (46.4%) | 0.533 | 169 (92.3%) | 14 (7.7%) | 0.024 | 8 (4.4%) |
175 (95.6%) | 0.477 |
| 2 | 265 (40.1%) | 93 (35.1%) | 172 (64.9%) | 148 (55.8%) | 117 (44.2%) | 222 (83.8%) | 43 (16.2%) | 18 (6.8%) | 246 (93.2%) | ||||
| 3 | 213 (32.2%) | 74 (34.7%) | 139 (65.3%) | 108 (50.7%) | 105 (49.3%) | 188 (88.3%) | 25 (11.7%) | 15 (7.0%) | 198 (93.0%) | ||||
| Nuclear grade | |||||||||||||
| 1 | 79 (12.0%) | 26 (32.9%) | 53 (67.1%) | 0.882 | 46 (58.2%) | 33 (41.8%) | 0.564 | 73 (92.4%) |
6 (7.6%) |
0.315 | 4 (5.1%) |
75 (94.9%) | 0.129 |
| 2 | 341 (51.6%) | 121 (35.5%) | 220 (64.5%) | 184 (54.0%) | 157 (46.0%) | 294 (86.2%) | 47 (13.8%) | 16 (4.7%) | 324 (95.3%) | ||||
| 3 | 241 (36.5%) | 82 (34.0%) | 159 (66.0%) | 124 (51.5%) | 307 (46.4%) | 212 (88.0%) | 29 (12.4%) | 21 (8.7%) | 220 (93.8%) | ||||
| Lymphovascular invasion | |||||||||||||
| Absent | 476 (72.0%) | 170 (35.7%) | 306 (64.3%) | 0.354 | 262 (55.0%) | 214 (45.0%) | 0.219 | 422 (88.7%) | 54 (11.3%) | 0.184 | 25 (5.3%) | 450 (94.7%) | 0.106 |
| Present | 185 (28.0%) | 59 (31.9%) | 126 (68.1%) | 92 (49.7%) | 93 (50.3%) | 157 (84.9%) | 28 (12.4%) | 16 (8.6%) | 169 (91.4%) | ||||
| Perineural invasion | |||||||||||||
| Absent | 597 (90.3%) | 208 (34.8%) | 389 (65.2%) | 0.746 | 323 (54.1%) | 274 (45.9%) | 0.388 | 523 (87.6%) | 74 (12.4%) | 0.981 | 36 (6.0%) | 560 (94.0%) | 0.577 |
| Present | 64 (9.7%) |
21 (32.8%) | 43 (67.2%) | 43 (65.4%) | 33 (51.6%) | 56 (87.5%) |
8 (12.5%) | 5 (7.8%) |
59 (92.2%) | ||||
| T stage | |||||||||||||
| T1 | 335 (50.7%) | 115 (34.3%) | 220 (65.7%) | 0.257 | 189 (56.4%) | 146 (43.6%) | 0.172 | 300 (89.6%) | 35 (10.4%) | 0.464 | 17 (5.1%) | 318 (94.9%) | <0.001 |
| T2 | 277 (41.9%) | 103 (37.2%) | 174 (62.8%) | 142 (51.3%) | 135 (48.7%) | 237 (85.6%) | 40 (14.4%) | 16 (5.8%) | 260 (94.2%) | ||||
| T3 | 44 (6.7%) |
10 (2.7%) | 34 (77.3%) | 19 (43.3%) | 25 (56.8%) | 38 (86.4%) |
6 (13.6%) | 5 (11.4%) | 39 (88.6%) | ||||
| T4 | 5 (0.8%) |
1 (20.0%) | 4 (80.0%) | 4 (80.0%) |
1 (20.0%) |
4 (80.0%) |
1 (20.0%) | 3 (60.0%) | 2 (40.0%) |
||||
| Lymph node metastasis | |||||||||||||
| Absent | 411 (62.2%) | 151 (36.7%) | 260 (63.3%) | 0.147 | 231 (56.2%) | 180 (43.8%) | 0.080 | 363 (88.3%) | 48 (11.7%) | 0.467 | 19 (4.6%) | 392 (95.4%) | 0.030 |
| Present | 250 (37.8%) | 78 (31.2%) | 172 (68.8%) | 123 (49.2%) | 127 (50.8%) | 216 (86.4%) | 34 (13.6%) | 22 (8.8%) | 227 (91.2%) | ||||
| M stage | |||||||||||||
| M0 | 640 (96.8%) | 228 (35.6%) | 412 (64.4%) | 0.002b | 349 (54.5%) | 291 (45.5%) | 0.007b | 563 (88.0%) | 77 (12.0%) | 0.165b | 36 (5.6%) | 604 (94.4%) | 0.007b |
| M1 | 21 (3.2%) |
1 (4.8%) |
20 (95.2%) | 5 (23.8%) |
16 (76.2%) | 16 (76.2%) |
5 (23.8%) | 5 (23.8%) | 16 (76.2%) | ||||
| AJCC stage | |||||||||||||
| Ⅰ | 249 (37.7%) | 86 (34.5%) | 163 (65.5%) | 0.001 | 141 (56.6%) | 108 (43.4%) | 0.001 | 225 (90.4%) | 24 (9.6%) | 0.135 | 10 (4.0%) | 239 (96.0%) | <0.001 |
| Ⅱ | 278 (42.1%) | 112 (40.3%) | 166 (59.7%) | 161 (57.9%) | 117 (42.1%) | 243 (87.4%) | 35 (12.6%) | 13 (4.7%) | 265 (95.3%) | ||||
| Ⅲ | 113 (17.1%) | 30 (26.5%) | 83 (73.5%) | 47 (41.6%) | 66 (58.4%) |
(84.1%) |
18 (15.9%) | 13 (11.5%) | 100 (88.5%) | ||||
| Ⅳ | 21 (3.2%) |
1 (4.8%) |
20 (95.2%) | 5 (23.8%) |
16 (76.2%) | 16 (76.2%) |
5 (12.4%) | 5 (23.8%) | 16 (76.2%) | ||||
| ER status | |||||||||||||
| Negative | 262 (39.6%) | 98 (37.4%) | 164 (62.6%) | 0.227 | 147 (56.1%) | 115 (43.9%) | 0.286 | 237 (90.5%) | 25 (9.5%) | 0.070 | 18 (6.9%) | 244 (93.1%) | 0.570 |
| Positive | 399 (60.4%) | 131 (32.8%) | 268 (67.2%) | 207 (51.9%) | 192 (48.1%) | 342 (85.7%) | 57 (14.3%) | 23 (5.8%) | 375 (94.2%) | ||||
| PR status | |||||||||||||
| Negative | 300 (45.4%) | 116 (38.7%) | 184 (61.3%) | 0.048 | 176 (58.7%) | 124 (41.3%) | 0.016 | 266 (88.7%) | 34 (11.3%) | 0.446 | 19 (6.4%) | 280 (93.6%) | 0.890 |
| Positive | 361 (54.6%) | 113 (31.3%) | 248 (68.7%) | 178 (49.3%) | 183 (50.7%) | 313 (86.7%) | 48 (13.3%) | 22 (6.1%) | 339 (93.9%) | ||||
| HER2 status | |||||||||||||
| Negative | 494 (74.7%) | 170 (34.4%) | 324 (65.6%) | 0.830 | 258 (52.2%) | 236 (47.8%) | 0.239 | 432 (87.4%) | 62 (12.6%) | 0.846 | 27 (5.5%) | 466 (94.5%) | 0.179 |
| Positive | 167 (25.3%) | 59 (35.3%) | 108 (64.7%) | 96 (57.5%) | 71 (42.5%) | 147 (88.0%) | 20 (12.0%) | 14 (8.4%) | 153 (91.6%) | ||||
| Intrinsic subtype | |||||||||||||
| Luminal | 448 (67.8%) | 147 (32.8%) | 301 (67.2%) | 0.343 | 233 (52.0%) | 215 (48.0%) | 0.240 | 388 (86.6%) | 60 (13.4%) | 0.536 | 24 (5.4%) | 423 (94.6%) | 0.177 |
| HER2 positive | 96 (14.5%) | 36 (37.5%) | 60 (62.5%) | 59 (61.5%) | 55 (47.0%) | 86 (89.6%) |
10 (10.4%) | 10 (10.4%) | 86 (89.6%) | ||||
| Triple negative | 117 (17.7%) | 46 (39.3%) | 71 (60.7%) | 62 (53.0%) | 55 (47.0%) | 105 (89.7%) | 82 (12.4%) | 7 (6.0%) |
110 (94.0%) | ||||
NLR, neutrophil-lymphocyte ratio; dNLR, derived neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor
aThe parameters are presented as the mean (standard deviation). Student’s t-test was used for comparisons between the two groups.
bFisher’s exact test was used for comparisons between the two groups.
cThis variable includes modified radical mastectomy and radical mastectomy.